Role of Acetylcysteine in Creatinine Clearance

Creatinine Clearance Clinical Trial

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00396396
• Other study ID #: EVMS 06-03-FB-0044
• Status: Unknown status
• Phase: N/A
• First received: November 3, 2006
• Last updated: November 3, 2006
• Start date: October 2006

Study information

• Verified date: November 2006
• Source: Eastern Virginia Medical School
• Contact: Ritche Chiu, MD
• Phone: 757-680-0211
• Email: dr_ritchechiu[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the exact role of Acetylcysteine (Mucomyst) in altering creatinine clearance. Prior studies have shown the protective effects of Acetylcysteine on contrast-induced renal dysfunction. In these studies, Acetylcysteine lowered the incidence of serum creatinine elevation after administration of radiographic contrast agents. Not only was the increase in serum creatinine prevented, the studies also demonstrated a significant increase in creatinine clearance after administration of the agent. These prior studies did not evaluate if the increase in creatinine clearance was indeed from a protective benefit of Acetylcysteine in preserving the GFR versus simply increasing the proximal tubular creatinine secretion without actually affecting the GFR. We propose an experiment to help support our hypothesis that Acetylcysteine increases creatinine clearance via an increase in proximal tubular secretion of creatinine.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 35
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Between the ages of 18 and 79 years

2. In good general health

3. Able to provide informed consent

Exclusion Criteria:

1. Allergy to acetylcysteine or cimetidine,

2. Age less than 18 years or greater than 79 years of age,

3. Women of childbearing age and not able to use adequate contraception, or 4. Anyone currently on any medication that interferes with tubular secretion of creatinine such as trimethoprim-sulfamethoxazole (Bactrim).

Related Conditions & MeSH terms

• Creatinine Clearance

Intervention

Drug:
• Acetylcysteine

Locations

Country	Name	City	State
United States	Eastern Virginia Medical School/Nephrology Associates	Norfolk	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Eastern Virginia Medical School

Country where clinical trial is conducted

United States,